🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Continuous glucose monitor data on semaglutide — what worked for you? Page 8

Continuous glucose monitor data on semaglutide — what worked for you?

julia.endo Fri, Sep 19, 2025 at 1:25 AM 42 replies 1,461 viewsPage 8 of 9
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
Jan 20, 2026 at 12:07 AM#36
PeptideChemSF said:
It helps to ask what evidence would change your mind before you look at any.

Coming at PeptideChemSF’s question from a different direction. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

I would rather be corrected than agreed with, if it comes to it.

9 7sarah_TO, wendy_avl, jason_paloalto and 6 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jan 26, 2026 at 10:18 PM#37

The figures, for anyone assembling their own picture. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

10 8stefan_berlin, Dr.EM_Chicago, pete_RVA and 7 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Feb 2, 2026 at 8:25 PM#38

A narrower follow-up, since the general answer is now clear:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

Last edited: Feb 2, 2026 at 9:25 PM
11 9LindaRN_retired, tommy_boulder, hyun_seoul and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Feb 9, 2026 at 6:28 PM#39
TrialTracker_MD said:
Keep the original post as written when you update it, and add the correction underneath.

Pushing back on TrialTracker_MD here. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

I would rather be corrected than agreed with, if it comes to it.

12 10LibrarianMeg, bri_stats, pete_manc_UK and 9 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Feb 16, 2026 at 4:27 PM#40
TrialTracker_MD said:
Keep the original post as written when you update it, and add the correction underneath.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Worth separating that from glycaemic control, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

34 7Dr.LipidDallas, alex_tucson, kevin_tulsa and 31 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register